<DOC>
	<DOC>NCT00151957</DOC>
	<brief_summary>This study will evaluate the long-term safety of MTS in the symptomatic treatment of children aged 6-12 diagnosed with ADHD</brief_summary>
	<brief_title>Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD and Previously Participated in MTS Trials</brief_title>
	<detailed_description>Attention-Deficit/Hyperactivity Disorder (ADHD) is a psychiatric disorder characterized by 3 main symptoms: inattention, hyperactivity and impulsivity. This study will evaluate the long-term safety of SPD485 in the symptomatic treatment of children aged 6-12 diagnosed with ADHD</detailed_description>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Subject must have participated in and completed SPD485201 or participated in and completed a minimum of five of the seven weeks of doubleblind treatment in study SPD485302. Subjects who are participating in N17021 may enroll in this study following completion of the End of Study/Termination visit procedures. Females of childbearing potential must have a negative urine pregnancy test at Baseline and must abstain from sexual activity that could result in pregnancy, or use acceptable contraceptives. Subject was terminated from SPD485102, SPD495201, SPD485302 OR N17021 for noncompliance or experienced a serious adverse event resulting in termination from the antecedent protocols Female subject is pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>